Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

$IMVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $IMVT alert in real time by email

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented.

Late-Breaking Oral Presentation Details:

Title:Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves' Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study
Presentation:#0020
Session:#5 – Autoimmune Thyroid Disease
Date and Time:Friday, November 1, 2024, 4:05pm – 5:05pm ET
Presenter:George Kahaly, MD, PhD
  

About Graves' disease

Graves' disease is an autoimmune disorder associated with the overproduction of thyroid hormones and is the most common cause of hyperthyroidism. Although Graves' disease can affect any age group or gender, it occurs often in women younger than 40 years of age. In Graves' disease, harmful IgG autoantibodies bind to and activate the thyroid-stimulating hormone receptor present on the thyroid gland, stimulating excess thyroid hormone production. Existing treatments, which include antithyroid drugs, radioactive iodine, and thyroid surgery, are aimed at reducing thyroid hormone levels to lessen the severity of symptoms. These treatments have remained largely unchanged for the past 70 years.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contact:

Renee Barnett, MBA

Chief Financial Officer

Immunovant, Inc.

info@immunovant.com

Source: Immunovant, Inc.



Primary Logo

Get the next $IMVT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What recent announcement did Immunovant, Inc. make regarding batoclimab?

    Immunovant, Inc. announced that data from the Phase 2a trial of batoclimab will be presented at the 2024 American Thyroid Association Annual Meeting.

  • What is the title of the oral presentation concerning batoclimab?

    The presentation is titled 'Efficacy and Safety of the FcRn Inhibitor, Batoclimab, in Graves' Thyroidal and Extrathyroidal Disease: a Proof-of-concept Study'.

  • When will the oral presentation about batoclimab take place?

    The oral presentation is scheduled for Friday, November 1, 2024, from 4:05 PM to 5:05 PM ET.

  • What is Graves' disease and why is it significant?

    Graves' disease is the most common cause of hyperthyroidism and is an autoimmune disorder that can lead to excessive thyroid hormone production.

  • What is the core mission of Immunovant, Inc. as a clinical-stage immunology company?

    Immunovant, Inc. is focused on developing therapies for autoimmune diseases, specifically utilizing anti-FcRn technology.

Recent Analyst Ratings for
$IMVT

DatePrice TargetRatingAnalyst
3/3/2025$20.00Hold
Jefferies
1/3/2025Outperform → Peer Perform
Wolfe Research
10/10/2024$36.00Outperform
Raymond James
10/9/2024$47.00 → $53.00Outperform
Oppenheimer
3/28/2024$50.00Outperform
Oppenheimer
3/13/2024$50.00Buy
Goldman
2/20/2024$51.00Overweight
JP Morgan
2/15/2024$55.00Outperform
Wolfe Research
More analyst ratings

$IMVT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

    Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IMVT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IMVT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$IMVT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IMVT
SEC Filings

See more

$IMVT
Leadership Updates

Live Leadership Updates

See more
  • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

    Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Immunovant Appoints Mark Levine as Chief Legal Officer

    Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Immunovant Appoints Renee Barnett as Chief Financial Officer

    Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IMVT
Financials

Live finance-specific insights

See more
  • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

    Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

    Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$IMVT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more